Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2021 Apr;27(4):603-610.
doi: 10.1016/j.cmi.2020.11.035. Epub 2020 Dec 8.

Corticosteroids in patients hospitalized for COVID-19 pneumonia who require oxygen: observational comparative study using routine care data

Collaborators, Affiliations
Observational Study

Corticosteroids in patients hospitalized for COVID-19 pneumonia who require oxygen: observational comparative study using routine care data

Viet-Thi Tran et al. Clin Microbiol Infect. 2021 Apr.

Abstract

Objective: To assess the effectiveness of corticosteroids on outcomes of patients with coronavirus disease 2019 (COVID-19) pneumonia requiring oxygen without mechanical ventilation.

Methods: We used routine care data from 51 hospitals in France and Luxembourg to assess the effectiveness of corticosteroids at 0.8 mg/kg/day eq. prednisone (CTC group) versus standard of care (no-CTC group) among adults 18-80 years old with confirmed COVID-19 pneumonia requiring oxygen without mechanical ventilation. The primary outcome was intubation or death by day 28. In our main analysis, characteristics of patients at baseline (i.e. time when patients met all inclusion criteria) were balanced by using propensity-score inverse probability of treatment weighting.

Results: Among the 891 patients included in the analysis, 203 were assigned to the CTC group. Use of corticosteroids was not significantly associated with risk of intubation or death by day 28 (weighted hazard ratio (wHR) 0.92, 95%CI 0.61-1.39) nor cumulative death rate (wHR 1.03, 95%CI 0.54-1.98). However, use of corticosteroids was associated with reduced risk of intubation or death by day 28 in the prespecified subgroups of patients requiring oxygen ≥3 L/min (wHR 0.50, 95%CI 0.30-0.85) or C-reactive protein level ≥100 mg/L (wHR 0.44, 95%CI 0.23-0.85). The number of hyperglycaemia events was higher for patients with corticosteroids than for those without, but the number of infections was similar.

Conclusions: We found no association between the use of corticosteroids and intubation or death in the broad population of patients 18-80 years old, with COVID-19, hospitalized in settings non intensive care units. However, the treatment was associated with a reduced risk of intubation or death for patients with ≥3 L/min oxygen or C-reactive protein level ≥100 mg/L at baseline. Further research is needed to confirm the right timing for corticosteroids in patients with COVID-19 requiring oxygen only.

Keywords: COVID-19; Causal inference; Corticosteroids; Observational study; Therapeutic evaluation.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Study flow chart. To account for immortal time bias, we randomly assigned patients who met the primary outcome during the grace period between the corticosteroid (CTC) and no-CTC groups.
Fig. 2
Fig. 2
Cumulative event curve for intubation or death in the unweighted and inverse probability of treatment weighting (IPTW) sample. ATE, average treatment effect.
Fig. 3
Fig. 3
Cumulative event curve for death in the unweighted and inverse probability of treatment weighting (IPTW) sample. ATE, average treatment effect.
Fig. 4
Fig. 4
Effect of corticosteroids on 28-day intubation or death in subgroups defined by oxygen requirement, C-reactive protein (CRP) level and time from symptom onset, at baseline. CTC, corticosteroids; HR, hazard ratio; 95%CI: 95% confidence interval.

References

    1. Tay M.Z., Poh C.M., Rénia L., MacAry P.A., Ng L.F.P. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020;20:363–374. - PMC - PubMed
    1. Bhimraj A., Morgan R.L., Shumaker A.H., Lavergne V., Baden L., Cheng V.C. Infectious diseases society of America guidelines on the treatment and management of patients with COVID-19. Clin Infect Dis. 2020 doi: 10.1093/cid/ciaa478. Apr 27. - DOI - PMC - PubMed
    1. Fadel R., Morrison A.R., Vahia A., Smith Z.R., Chaudhry Z., Bhargava P. Early short course corticosteroids in hospitalized patients with COVID-19. Clin Infect Dis. 2020;71:2114–2120. doi: 10.1093/cid/ciaa601. - DOI - PMC - PubMed
    1. Wu J., Huang J., Zhu G., Liu Y., Xiao H., Zhou Q. Systemic corticosteroids and mortality in severe and critical COVID-19 patients in Wuhan, China. J Clin Endocrinol Metab. 2020;105:e4230–e4239. doi: 10.1210/clinem/dgaa627. - DOI - PMC - PubMed
    1. Bani-Sadr F., Hentzien M., Pascard M., N’Guyen Y., Servettaz A., Andreoletti L. Corticosteroid therapy for patients with COVID-19 pneumonia: a before–after study. Int J Antimicrob Agents. 2020;56:106077. - PMC - PubMed

Publication types